Skip to content

Comparison of 7 days versus 14 days antibiotics for patients hospitalized with non-severe kidney infection

Comparison of 7 days versus 14 days antibacterial treatment for hospitalized non-severe acute pyelonephritis patients-a randomized controlled trial

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/04/006810
Enrollment
62
Registered
2016-04-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Acute pyelonephritis Health Condition 2: N390- Urinary tract infection, site notspecified

Interventions

Intervention1: 7 days antibacterial treatment: In the intervention arm, patients admitted with acute pyelonephritis are given a total of 7 days of sensitive antibiotic/antibiotics. The choice of the a

Sponsors

Department of Medicine Jawaharlal Institute of Postgraduate Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Either sex aged >18 years, admitted for acute pyelonephritis, defined as fever of at least 38oC and at least one symptom or sign relating to the urinary tract such as flank pain, costovertebral angle tenderness, dysuria, urgency or frequency along with the microbiologic criteria (>=10 pus cells/hpf or dipstick leucocyte esterase test positive and a positive culture with >=10 5 CFU/ mL of urine). They should have improved with empirical or culture-guided antibiotic treatment and be afebrile for at least 48 hours by day 7 of antibiotic treatment.

Exclusion criteria

Exclusion criteria: •Catheter-associated UTI •Recurrent UTI •Obstructive uropathy •Residual bladder urine >100 ml •Acute or chronic prostatitis / prostatic abscess • Emphysematous PN/renal or perinephric abscess •Shock requiring vasopressors •Altered sensorium requiring intubation (GCS score •Acute lung injury requiring mechanical ventilation •Renal failure requiring RRT •Clinically manifest DIC •Pregnancy •Any immunosuppressive treatment

Design outcomes

Primary

MeasureTime frame
Re-treatment rates within 6 weeks (Due to clinical or microbiological failure) Timepoint: Re-treatment rates within 6 weeks (Due to clinical or microbiological failure)

Secondary

MeasureTime frame
1.Duration of hospital stay 2.Daily defined dose of antibiotics 3.Asymptomatic bacteriuria 4.Adverse affects of antibiotics Timepoint: 1. At the time of discharge 2.During the hospital stay 3. At 6 weeks 4. During the hospital stay

Countries

India

Contacts

Public ContactDeepanjali S

JIPMER

pavankumarrudrabhatla@gmail.com9159525608

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 24, 2026